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Abstract
Background: An assessment of the accuracy of two malaria rapid diagnostic tests (RDT) for the
detection of Plasmodium falciparum histidine-rich protein 2 (PfHRP2) or Pf lactate dehydrogenase
(PfLDH) was undertaken in children aged between six and 59 months included in an anti-malarial
efficacy study in Benin.
Methods: In Allada (Benin), 205 children aged 6-59 months with falciparum malaria received either
artesunate-amodiaquine (ASAQ), artemether-lumefantrine (AL), or sulphadoxine-pyrimethamine
(SP). Children included in the study were simultaneously followed by both RDT and high-quality
microscopy for up to 42 days.
Results: At the time of inclusion, PfHRP2-based tests were positive in 203 children (99%) and
PfLDH-based tests were positive in 204 (99.5%). During follow-up, independent of the treatment
received, only 17.3% (28/162) of children effectively cured were negative with the PfHRP2 RDT at
day 3, with a gradual increase in specificity until day 42. The specificity of antigen detection with the
PfLDH test was 87% (141/162) on day 3, and between 92% and 100% on days 7 to 42. A statistical
difference was observed between the persistence of PfHRP2 and PfLDH antigenaemia during
follow-up in children treated with artemisinin-based combination therapy (ACT) but not with SP.
Conclusion: Although both RDTs are as sensitive as microscopy in detecting true malaria cases,
the PfHRP2 RDT had very low specificity during follow-up until day 28. On the other hand, the
PfLDH test could be used to detect failures and, therefore, to assess anti-malarial efficacy.
Background
In response to increased anti-malarial drug resistance,
artemisinin-based combination therapy (ACT) is recom-
mended in Africa [1]. Due to the significantly higher cost
of ACT than drugs formerly used, such as chloroquine and
sulphadoxine-pyrimethamine (SP), strong emphasis has
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been placed on the importance of avoiding any unneces-
sary use of ACT, so as to minimize opportunities for the
development of parasite drug resistance to it. Since clini-
cal diagnosis is non-specific, laboratory confirmation is
essential for accurate diagnosis of malaria. However,
although microscopy is still considered the gold standard,
it is unavailable in many endemic areas. An alternative is
the use of a rapid diagnostic test (RDT) that is simple to
perform, requires neither equipment nor electricity, and
provides a result within 15 to 20 minutes [2].
The numerous commercially available RDTs fall into two
categories [3]. One group of RDTs detects histidine-rich
protein 2 (PfHRP2), uniquely synthesized by Plasmodium
falciparum present in the bloodstream of infected individ-
uals. The second group of RDTs detects parasite lactate
dehydrogenase (PspLDH), an enzyme produced by all
four Plasmodium species responsible for human malaria,
and may also detect species-specific LDH, such as PfLDH,
specific of P. falciparum, or PvLDH, specific of Plasmodium
vivax.
Although, PfHRP2 test kits have generally shown higher
sensitivity for P. falciparum and can be less costly than the
PspLDH alternative, studies have shown that PfHRP2
remains in the bloodstream for an extended time follow-
ing successful eradication of the parasite, thus contribut-
ing to false-positive results and limiting specificity [4]. A
recent study has shown day-14 and day-21 PfHRP2 false-
positivity rates of 98.2% and 94.6%, respectively [5]. In
order to monitor the success of anti-malarial drug therapy
particularly in the presence of fever, it is critical to accu-
rately differentiate between a new episode of malaria and
another cause. Due to the increase in drug-resistant infec-
tions, it has been suggested that PspLDH-based tests are
more useful for this purpose, since they become negative
soon after parasite clearance from the blood [4,6]. How-
ever, the presence of gametocytes could give a false-posi-
tive result, especially if high gametocytaemia persists [7].
ACT could modify this situation because of its rapid effect
and anti-gametocyte action [8].
Therefore, in conjunction with an anti-malarial efficacy
study underway in Benin, the accuracy of two commercial
malaria RDTs in diagnosing and monitoring malaria treat-
ment was evaluated. The RDTs studied were Immuno-
quick® Malaria (Biosynex, Strasbourg, France), a PfHRP2-
based test, and Optimal® IT (Diamed, Cressier, Switzer-
land), a PspLDH-PfLDH-based test. The results obtained
with these two tests were compared with those obtained
using a thick blood film. The kinetics of the disappearance
of PfHRP2 and PfLDH antigens following treatment were
also studied. The performances of both RDTs were
assessed during follow-up.
Methods
Study site
The RDT assessment took place concurrently with a 42-
day ACT efficacy trial that conformed to WHO guidelines,
which has been described elsewhere [9]. In brief, Benin is
an African country in which malaria is highly endemic
and seasonal, with peaks during the low (March to May)
and high (September to November) rainy seasons. The
study site consisted of two small towns, Allada and Sekou,
in the south of Benin, 50 km north of Cotonou, the capi-
tal. Plasmodium falciparum accounts for 95% of the Plasmo-
dium species in this region. Study approval was obtained
from the ethics committee of the Benin National Malaria
Program.
Study design
The RDT assessment was carried out between April and
November 2007. After screening febrile children aged
between six and 59 months, those confirmed with falci-
parum malaria, who met inclusion criteria for the ACT effi-
cacy study were recruited after their guardians had
provided informed written consent. Two rapid diagnostic
tests were conducted, the PfHRP2-based Immunoquick®
Malaria (Biosynex, Strasbourg, France) and the PspLDH-
PfLDH-based Optimal®  IT (Diamed, Cressier, Switzer-
land).
Children were randomized to receive either artesunate +
amodiaquine (ASAQ), artemether + lumefantrine (AL), or
sulphadoxine-pyrimethamine (SP). Most of the children
were followed up to assess both anti-malarial efficacy and
duration of false-positive RDT results, as defined by posi-
tive RDT and continued negative microscopy after anti-
malarial treatment. For purposes of RDT assessment, fol-
low-up was conducted by clinical examination and finger-
prick blood samples on days 3, 7, 14, 21, 28, 35, and 42
post-treatment, or on any other day if the child was
unwell.
Laboratory procedures
Blood films and rapid tests were carried out on the same
finger-prick blood sample. A thick blood film for micro-
scopic detection of parasites was prepared and stained
with 10% Giemsa. The thick films were read by experi-
enced technicians. Asexual parasites were counted against
200-500 leukocytes and converted to the number of para-
sites per unit volume, assuming 8,000 leukocytes/μL
blood [10]. Gametocytes were reported after examining
100 microscopic fields. Slides were considered negative if
no parasites were detected after viewing 100 microscope
fields. Microscopists were unaware of patient treatment
allocation.
Internal quality control included a blind second reading
of a portion of the slides as follows: all slides taken duringMalaria Journal 2009, 8:211 http://www.malariajournal.com/content/8/1/211
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days 0 and 3, all positive slides after day 3, and 20% of
negative slides. All day-28 and day-35 negative slides were
reread. In case of a discrepancy, two technicians re-exam-
ined the slides together and mutually decided on the read-
ing. External controls were conducted by a Benin Ministry
of Health government reference laboratory in the provin-
cial capital, Cotonou.
The RDT tests were obtained directly from the manufac-
turers and stored in their original packaging at room tem-
perature. Package desiccant quality was checked before
using the tests [11]. All RDTs were labeled with patient ID
numbers, carried out, and interpreted according to the
manufacturers' instructions. All RDTs were read visually,
and a control line was established for the purpose of vali-
dating the test. For cases in which the control line did not
appear, the result was considered invalid and the test
repeated. For the PfHRP2-based test, results were recorded
15 minutes after placing the strip into six drops (300 μL)
of buffer. The presence of both the control and test lines
indicated a positive result for P. falciparum; the presence of
the control line alone indicated a negative result. Results
were recorded after 20 minutes for the PfLDH-based test.
For PfLDH, the presence of the test line indicated a posi-
tive result for P. falciparum, and the presence of the test
line for PspLDH indicated a positive result for Plasmodium
species, including P. falciparum. The technician recording
the RDT result was unaware of the corresponding micros-
copy results. Internal quality control included an immedi-
ate blind second reading of 100% of the RDTs. In case of
disagreement, two technicians re-examined the RDT
together and decided on the reading.
Analysis
Specificity, sensitivity, and predictive values of the RDT
[with a confidence interval of 95% (95% CI)] were esti-
mated using microscopy as the denominator for compar-
ison. Sensitivity was defined as the percentage of positive
tests among the total number of positive blood slides.
Specificity was defined as the percentage of negative tests
among the total number of negative blood slides. The pos-
itive predictive value (PPV) was defined as the percentage
of positive blood slides among the total number of posi-
tive tests. The negative predictive value (NPV) was defined
as the percentage of negative blood slides among the total
number of negative tests. The percentage of false-positive
(FP) tests was defined as the percentage of tests that
remained positive during follow-up once the blood sam-
ple was negative by microscopy for asexual-stage parasites.
The presence of gametocytes alone was not considered to
be a positive microscopy result. Categorical variables were
compared using the Fisher or X2 exact tests, in accordance
with the number of patients. A p value of <0.05 was con-
sidered statistically significant.
Results
Characteristics of study subjects
Between March and September 2007, 205 children pre-
senting with fever and a P. falciparum parasitaemia above
1,000/μL were included in the study. Parasite densities
ranged between 1,000 and 525,000 parasites/μl.
The children were divided into three groups, according to
their treatment allocation: 81 were treated with the AL
combination, 80 with the ASAQ combination, and 44
with the SP combination. During the six-week follow-up
period, 80 children were followed to day 42 and 40 chil-
dren were followed to day 28. Among the children
included in the three groups, 72 were given additional
treatment within 35 days, due to malaria recrudescence or
re-infection (and were excluded from the RDT study after
this second treatment), and 13 children were lost to fol-
low-up. Detailed results of the efficacy study have been
published [9]. Seven gametocyte carriers were diagnosed
during the follow-up (two in the AL treatment group, one
in the ASAQ treatment group, and four in the SP treat-
ment group.)
RDT validity
On day 0, similar sensitivities were observed with both
RDTs. The PfHPR2-based tests were positive for 203 chil-
dren (99%, [95% CI: 96.5-99.7]) and the PfLDH-based
tests were positive for 204 (99.5%, [95% CI: 97.3-99.9]).
PspLDH and PfLDH detection yielded similar results dur-
ing the study. Since only children with P. falciparum
malaria were included in the study, only PfLDH detection
results are presented and compared with PfHRP2 detec-
tion.
Relatively few samples were positive by microscopy dur-
ing the days following treatment. Thirty-five samples were
positive on day 3, seven on days 7 and 14, 16 on day 21,
15 on day 28, 11 on day 35, and three on day 42 (Table
1). Sensitivity decreased with day of follow-up for both
the PfHPR2-based test (from 100% on day 3 to 67% on
day 42) and the PfLDH-based test (from 80% on day 3 to
67% on day 42) (Table 1). On the other hand, specificity
increased during follow-up, going from 17% on day 3 to
95% on day 42 for the PfHPR2-based test and from 87%
on day 3 to 100% on day 42 for the PfLDH-based test
(Table 2). From day 3 to day 28 of follow-up, the specifi-
city of the PfLDH-based test was statistically higher than
that of the PfHRP2-based test (Table 2). Negative predic-
tive values (except one) during follow-up were greater
than 95% (Table 3) for both the PfHPR2- and PfLDH-
based tests. On the contrary, positive predictive values
were not satisfactory for either RDT (less than 80%),
except for PfLDH-based tests carried out on day-28 sam-
ples (Table 4).Malaria Journal 2009, 8:211 http://www.malariajournal.com/content/8/1/211
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Effect of parasite density and PfHRP-2 persistence
Figure 1 shows the proportion of false-positive results
obtained during follow-up for PfHRP2 and PfLDH anti-
gen detection as a function of parasite density at screen-
ing. Day-0 parasitaemia (number of parasites/μl) was
stratified into low (1,000 - 10,000; n = 78), middle
(10,000 - 50,000; n = 75), and high (50,000 - 525,000 (n
= 52). The proportion of children with low parasite den-
sity was lower than the proportion with high parasite den-
sity from day 7 to day 35 for PfHRP2-positive antigen
detection. Twenty-eight days after effective treatment, 8%
(4/50; 95% CI 3.1 - 18.9) of the children with low parasite
density had PfHRP2 false-positive results, compared to
42.9% (15/35; 95% CI 28.0 - 59.1) of those with high par-
asite density (p = 0.0004). In contrast, on any day during
follow-up, the proportion of false-positive PfLDH antigen
detection results was low and similar in all three groups
(Figure 1).
Table 1: Sensitivity of antigen detection with rapid diagnostic 
tests compared to blood slide microscopy during follow-up.
Sensitivity
PfLDH PfHRP2
% 95% CI % 95%CI
D3 80.0 (28/35) 64.1 - 90.0 100 (35/35) 90.1 - 100.0
D7 71.4 (5/7) 35.9 - 91.2 85.7 (6/7) 48.7 - 97.4
D14 71.4 (5/7) 35.9 - 91.2 85.7 (6/7) 48.7 - 97.4
D21 100 (16/16) 80.6 - 100.0 87.5 (14/16) 64.0 - 96.5
D28 86.7 (13/15) 62.1 - 96.3 86.7 (13/15) 62.1 - 96.3
D35 81.8 (9/11) 52.3 - 94.9 81.8 (9/11) 52.3 - 94.9
D42 66.7 (2/3) 20.8 - 93.9 66.7 (2/3) 20.8 - 93.9
Table 2: Specificity of antigen detection with rapid diagnostic 
tests compared to blood slide microscopy during follow-up.
Specificity
PfLDH PfHRP2
% 95%CI % 95%CI
D3 87.1 (141/162) *** 81.0 - 91.4 17.3 (28/162) 12.2 - 23.8
D7 92.0 (151/164) *** 86.9 - 95.3 29.9 (49/164) 23.4 - 37.3
D14 96.1 (150/156) *** 91.9 - 98.2 55.8 (87/156) 47.9 - 63.3
D21 96.5 (137/142) *** 92.1 - 98.5 73.2 (104/142) 65.4 - 79.8
D28 97.6 (122/125) *** 93.1 - 98.2 73.6 (92/155) 65.2 - 80.5
D35 97.6 (81/83) NS 91.6 - 99.3 95.2 (79/83) 88.2 - 98.1
D42 100.0 (77/77) NS 95.2 - 100.0 94.8 (73/77) 87.4 - 98.0
***: p < 0.0001; NS: p > 0.05
Table 3: Negative predictive value of antigen detection with 
rapid diagnostic tests compared to blood slide microscopy 
during follow-up.
Negative predictive value
PfLDH PfHRP2
% 95%CI % 95%CI
D3 95.3 (141/148) 90.6 - 97.7 100 (28/28) 87.9 - 100.0
D7 98.1 (151/154) 95.4 - 99.6 98.0 (49/50) 89.5 - 99.7
D14 98.7 (150/152) 95.3 - 99.6 98.9 (87/88) 93.8 - 99.8
D21 100 (137/137) 97.3 - 100.0 98.1 (104/106) 93.4 - 99.5
D28 98.4 (122/124) 94.3 - 99.6 97.9 (92/94) 92.6 - 99.4
D35 97.6 (81/83) 91.6 - 99.4 97.6 (81/83) 91.6 - 99.3
D42 98.7 (77/78) 93.1 - 99.8 98.7 (73/74) 92.7 - 99.8
Table 4: Positive predictive value of antigen detection with rapid 
diagnostic tests compared to blood slide microscopy during 
follow-up.
Positive predictive value
PfLDH PfHRP2
% 95% CI % 95%CI
D3 57.1 (28/49) 43.3 - 70.0 20.7 (35/169) 15.3 - 27.4
D7 27.8 (5/18) 12.5 - 50.9 5.0 (6/121) 2.2 - 10.4
D14 45.4 (5/11) 21.3 - 72.0 8.0 (6/75) 3.7 - 16.4
D21 76.2 (16/21) 54.9 - 89.4 26.9 (14/52) 16.8 - 40.2
D28 81.2 (13/16) 57.0 - 93.4 28.3 (13/46) 17.3 - 42.6
D35 81.8 (9/11) 52.3 - 94.9 69.2 (9/13) 42.4 - 87.3
D42 100.0 (2/2) 34.2 - 100.0 66.7 (4/6) 30.0 - 90.3Malaria Journal 2009, 8:211 http://www.malariajournal.com/content/8/1/211
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Effect of treatment on the kinetics of antigen 
disappearance
Independent of the treatment received, PfHRP2 antigen
persisted until day 35; indicating a high proportion of
false-positive results with the PfHPR2-based test (Figure
2). The proportion of false positive results was unrelated
to the treatment given. The specificity of PfLDH detection
differed among treatment allocations. After SP treatment,
there was no statistical difference between PfHRP2 and
PfLDH persistence. After AL and ASAQ treatments, fewer
false positive results were observed with PfLDH than with
PfHRP2 from day 3 to day 28, (all p < 0.01). Moreover,
after SP treatment, the proportion of false-positive results
obtained with the PfLDH-based test was high until day 14
(Figure 2). The specificity of the PfLDH-based test was
higher after ACT than after SP treatment from day 3 to day
14 (all p < 0.05). No correlation was found between the
presence of gametocytes and the duration of RDT positiv-
ity, except on day 7, when three among the 13 results were
false-positive (13/164) with the PfLDH-based test in
gametocyte carriers.
Evaluation of false-negative results
Possible reasons for negative results included low parasite
density and/or deficient in antigen parasites for both
PfHPR2 and PfLDH detection. PCR-amplified exon 2
PfHRP2 fragments were obtained on day 0 from the two
negative isolates with the PfHPR2-based test; therefore,
the parasites were not antigen-deficient. False-negative
results obtained during follow-up with both the PfHPR2-
and PfLDH-based tests could be explained by low parasite
densities, comprising between 16 and 800 parasites/μl.
Discussion
The results of this study reveal that the specificity of the
PfLDH-based test is below 90% only for a short time, up
to seven days after effective treatment. During days 3 to 28
post-treatment, PfLDH detection was more specific than
PfHRP2, as has been demonstrated in other studies
[12,13]. Since the production of both PspLDH and PfLDH
are both related to parasite viability [6], the rapid disap-
pearance of PfLDH in blood after treatment may be due to
parasite death following adequate treatment [14]. In addi-
tion, this study revealed a drug-related effect on the dura-
tion of PfLDH-based test positivity after treatment.
Proportion of children with false-positive PfHRP2-based test or PfLDH-based test during follow-up, stratified by day-0 parasite  density Figure 1
Proportion of children with false-positive PfHRP2-based test or PfLDH-based test during follow-up, stratified 
by day-0 parasite density. PfHRP2: parasite density: black triangle: 50,000 - 525,000 p/μL; black square: 10,000 - 50,000 p/μl; 
black diamond: 1,000 - 10,000 p/μl. PfLDH: parasite density: white triangle: 50,000 - 525,000 p/μL; white square: 10,000 - 
50,000 p/μl; white diamond: 1,000 - 10,000 p/μl.
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Following ACT, the persistence of PfLDH was of shorter
duration than that of PfHRP2. In addition, PfLDH false-
positivity lasted longer following SP treatment than with
ACT (until day 14). The rapid action of artemisinin deriv-
atives on all parasite blood stages could be the reason for
the fast clearance of PfLDH in blood [15].
The duration of false positivity of the PfHPR2-based test
can be as long as 28 days after effective treatment. As men-
tioned above, past evidence strongly suggests that, to a
large extent, this is due to the increased time it takes to
clear PfHPR2 from the blood following P. falciparum clear-
ance. The duration of false positivity observed in this
study with the PfHPR2-based test has been correlated to
higher parasite density on admission. Since secretion of
the protein is proportional to parasite numbers [16], a
higher parasite density on admission would require an
extended period of time for PfHPR2 to be cleared from
blood. The results of the present study further support this
point, indicating a strong correlation between the dura-
tion of PfHPR2-based test positivity and parasite density
at admission. Although the mechanism of PfHRP2 clear-
ance is not well understood, there are several explanations
for its long persistence following adequate therapy. As
previously suggested by Singh and Shukla [17], the
present study was designed to investigate whether the per-
sistence of PfHRP2 in blood after efficacious treatment
was influenced by the treatment. Indeed, artemisinin
derivatives are active during the Plasmodium ring stage,
leading to the rapid disappearance of parasites in blood
[15]. The production of PfHRP2, which is generated at all
Plasmodium stages, could be stopped earlier with ACT than
with SP, and a parallel quick clearance of PfHRP2 could
occur [18]. However, the results of the study did not sup-
port this hypothesis, since no difference was observed in
the persistence of PfHRP2 after treatment with either
artesunate or artemether (fast-acting artemisinin com-
pounds) or SP. In addition, PfHRP2 false-positives deter-
mined by comparison with microscopy results are
observed in identical proportions in all three treatment
groups during follow-up.
Proportion of true-negative and false-positive results for PfHPR2 and PfLDH according to the treatment during follow-up Figure 2
Proportion of true-negative and false-positive results for PfHPR2 and PfLDH according to the treatment during 
follow-up. (SP: sulphadoxine-pyrimethamine; ASAQ: artesunate-amodiaquine, AL: artemether-lumefantrine). Statistical analy-
sis of antigen detection specificities for ACT compared to SP and for PfLDH compared to PfHPR2 are shown on the right: ***: 
p0.001; **: p < 0.01: *: p < 0.05, ns: not significant.
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The reference method in this study was the microscopy
because according WHO recommendations, efficacy is
defined according to clinical and microscopy criteria [10].
Probably, PCR on account of its high sensitivity may have
given slightly different results but the efficiency of PCR to
manage treatment follow-up was not yet demonstrated.
PfHRP2 is also released by early gametocytes [19]. There-
fore, the persistence of immature gametocytes in blood
after successful therapy could result in the persistence of
PfHPR2 positivity [20]. In the studied population, what-
ever the treatment group, only a few gametocyte carriers
were detected. This study did not allow a conclusion
regarding the existence of an association between gameto-
cytaemia and duration of PfHRP2 or PfLDH detection
positivity, due to the small number gametocytes carriers.
The ACT effect on gametocytes did not account for the
shorter persistence of PfHRP2 compared to the effect of SP
therapy.
The results of this study reveal high PfHPR2- and PfLDH-
based test sensitivities compared with microscopy at the
time of screening. In contrast with other studies [21,22], a
high sensitivity was observed with the PfLDH-based test,
equivalent to that of the PfHPR2-based test. Previous stud-
ies may have been carried out using reagents whose qual-
ity had been altered by heat and/or humidity. Reagent
quality has now been improved and conservation is bet-
ter, even under drastic conditions [23]. The high parasite
levels in the children included in the study could also
explain this result [24]. Discrepancies were found in three
samples: two were positive with the PfHPR2-based test,
but negative with PfLDH-based test, and the third was
negative with the PfHPR2-based test but positive with
PfLDH-based test. No alteration was found by PCR in the
DNA of PfHRP2 and PfLDH genes that could explain the
false-negative RDT results obtained for these samples
[25,26].
In this study, for each day of follow-up, the sensitivities of
the tests to detect failures were between 67% and 100%,
but the numbers of relapsing patients were low (between
3 and 16), and the parasitaemia in positive samples not
detected by the tests was low. Whereas, for the diagnosis,
the performance of both RDT tests used in the study is
good as demonstrated by WHO with a sensitivity of 100%
for the PfHPR2-based test and 96.2% for the PfLDH-based
test against P. falciparum samples at parasites densities
more than 2,000/μl [24]. However, given its high specifi-
city, the predictive positive values of the PfLDH-based test
during follow-up were sufficient to consider a positive
result to be a strong presumption of relapse, especially
after ACT treatment.
Conclusion
In conclusion, Optimal®  IT allows detection of both
PspLDH and PfLDH and can be used during follow-up of
an in vivo drug sensitivity test to confirm the effectiveness
of anti-malarial treatment, especially after ACT or other
quick-acting drugs, or to confirm suspected relapse.
Immunoquick® Malaria allows detection of PfHRP2 and is
a good test for ruling out a diagnosis of malaria, but
should not be used during follow-up prior to day 35.
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